B Cell Engineering Service for Anti-Blastoma Antibody Delivery

Creative Biolabs specializes in B cell engineering service for anti-blastoma antibody delivery to support sciences research in immunology and related biomedical industry worldwide.

Background of Blastoma

Blastoma is caused by malignant tumors of precursor cells that occur in the developing cells of a fetus or child. Many types of blastoma are defined by the site of origin, including hepatoblastoma, nephroblastoma, retinoblastoma, pancreatoblastoma, and so on. Symptoms of blastoma depend on their location in the body, the size, and stage of the tumor. Current treatments for blastoma include surgery, radiotherapy, chemotherapy, and several novel targeted drugs.

B Cell Engineering Service for Anti-Blastoma Antibody Delivery at Creative Biolabs

Engineering human B cells to differentiate into long-lived plasma cells and secrete a nascent antibody, creating a new therapeutic pathway for blastoma diseases. With extensive experience and advanced platforms, Creative Biolabs has established a cutting-edge B cells genome editing platform that has the potential to aid cancer treatment. We offer a full range of high-quality B cell engineering services for anti-blastoma antibody delivery, including B cell isolation, B cell activation, B cell expansion, B cell engineering, and so on, to generate engineered B cell populations suitable for our clients' B cell research and project development.

Fig.1 B cell engineering associated service scheme. (Creative Biolabs)

A Full Range of Popular Targets Profile to Empower B Cell Engineering Service

We offer a full range of hot targets for blastoma, the following are some highly effective targets you can choose to engineer, including but not limited to:

Fig.2 Scheme of popular targets for blastoma. (Creative Biolabs)

Optimized Engineering Approaches to Facilitate B Cell Engineering Service

The efficiency and safety of delivery tools are major concerns in the genetic engineering of human primary B cells and plasma cells. We offer a variety of engineering methods for our customers to choose from, and we will optimize more appropriate and efficient options for customers based on our years of experience.

Published Data

• Paper Title: Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration.
• Summary: The investigators developed a convenient procedure to deliver Cas9/sgRNA and a corresponding donor template into human primary B cells by using an IDLV delivery system. These gene-edited B cells differentiated into LLPCs, both in vitro and in vivo in humanized mice, and maintained serum antibody titers for a long time. The results also demonstrated that the α-PD-1 mAb produced by these genetically engineered LLPCs had potent anti-tumor effects in melanoma-inoculated mice.
• Technology: CRISPR/Cas9 genetics method
• Cell type: human primary B cells
• Results

Fig.3 Schematic overview of targeting strategy for α-PD-1 integration. (Luo, et al., 2020)

Fig.4 Targeted transgene expression in human primary B cells. (Luo, et al., 2020)

Fig.5 The engineered B-cells secreting α-PD-1 mAb enhanced the antitumor activity of human T cells. (Luo, et al., 2020)

If you are interested in our B cell engineering services, please feel free to contact us to discuss your project further.

1. Luo, B.; et al. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. Cell Death & Disease. 2020, 11(11): 973.

Related Sections:

• Anti-Viruses Antibody Delivery
• Anti-Leukemia Antibody Delivery
• Anti-Lymphoma Antibody Delivery
• Anti-Sarcoma Antibody Delivery
• Anti-Glioma Antibody Delivery
• Anti-Germ Cell Tumor Antibody Delivery
• Anti-Autoimmune Diseases Antibody Delivery